This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

40/100

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Repulsive guidance molecule-a (RGMa) has emerged as a significant therapeutic target in a variety of neurological disorders, including neurodegenerative diseases and acute conditions. This review comprehensively examines the multifaceted role of RGMa in central nervous system (CNS) pathologies such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, neuromyelitis optica spectrum disorder, spinal cord injury, stroke, vascular dementia, auditory neuropathy, and epilepsy. The mechanisms through which RGMa contributes to neuroinflammation, neuronal degeneration, and impaired axonal regeneration are herein discussed. Evidence from preclinical studies associate RGMa overexpression with negative outcomes, such as increased neuroinflammation and synaptic loss, while RGMa inhibition, particularly the use of agents like elezanumab, has shown promise in enhancing neuronal survival and functional recovery. RGMa's responses concerning immunomodulation and neurogenesis highlight its potential as a therapeutic avenue. We emphasize RGMa's critical role in CNS pathology and its potential to pave the way for innovative treatment strategies in neurological disorders. While preclinical findings are encouraging so far, further clinical trials are needed to validate the safety and efficacy of RGMa-targeted therapies.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tseriotis, V., Liampas, A., Lazaridou, I.-Z., Karachrysafi, S., Vavougios, G. D., Hadjigeorgiou, G. M., et al. (2025). Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073221

Vancouver

Tseriotis V, Liampas A, Lazaridou I.-Z, Karachrysafi S, Vavougios GD, Hadjigeorgiou GM, et al. Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073221. PMID: 40244061.

BibTeX

@article{tseriotis2025-40244061,
  author  = {Tseriotis, Vasilis‐Spyridon and Liampas, Andreas and Lazaridou, Irene-Zacharo and Karachrysafi, Sofia and Vavougios, George D. and Hadjigeorgiou, Georgios M. and Papamitsou, Theodora and Kouvelas, Dimitrios and others},
  title   = {{Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update}},
  journal = {International Journal of Molecular Sciences},
  year    = {2025},
  doi     = {10.3390/ijms26073221},
  pmid    = {40244061},
  url     = {https://doi.org/10.3390/ijms26073221}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Repulsive guidance molecule-a (RGMa) has emerged as a significant therapeutic target in a variety of neurological disorders, including neurodegenerative diseases and acute conditions.

Why it matters

This review reports that in preclinical studies, blocking RGMa with agents like elezanumab improved neuronal survival and recovery, but these findings are not yet confirmed in people. The authors state that further clinical trials are needed to validate the safety and efficacy of RGMa-targeted therapies.

Study details

Evidence strengthLow

How this study scored 40/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (International Journal of Molecular Sciences)
Journal's citation record	3 / 4	International Journal of Molecular Sciences: journal h-index 426 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 9 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	3.0 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 2.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Theodorοs Mavridis: h-index 14 (OpenAlex, whole career)
Institution's track record	1 / 3	National and Kapodistrian University of Athens: institution h-index 859 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 9 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40244061)
Free to read	2 / 2	Free to read
Total	40 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Disease mechanisms

Also tagged “mice”

1,150 studies in the library carry the topic tag “mice”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →